Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma
Keywords:
Área de Medicina Clínica y Epidemiología
Mitogen-activated protein kinase pathway
Immunotherapy
B-cell lymphoma-2
Programmed death-ligand 1
Biomarker
Note:
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Citation:
Schjesvold, F.; Lourenco-Paiva, B. (Bruno David); Ribrag, V.; et al. "Cobimetinib alone and plus venetoclax with/without atezolizumab in patients with relapsed/refractory multiple myeloma". Clinical Lymphoma Myeloma and Leukemia. 23 (1), 2023, e59 - e70
Statistics and impact
0 citas en
0 citas en
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.